RT Journal Article
SR Electronic
T1 Reliability of self-sampling for accurate assessment of respiratory virus viral and immunologic kinetics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.03.20051706
DO 10.1101/2020.04.03.20051706
A1 Waghmare, Alpana
A1 Krantz, Elizabeth M.
A1 Baral, Subhasish
A1 Vasquez, Emma
A1 Loeffelholz, Tillie
A1 Chung, E. Lisa
A1 Pandey, Urvashi
A1 Kuypers, Jane
A1 Duke, Elizabeth R
A1 Jerome, Keith R.
A1 Greninger, Alexander L.
A1 Reeves, Daniel B.
A1 Hladik, Florian
A1 Cardozo-Ojeda, E. Fabian
A1 Boeckh, Michael
A1 Schiffer, Joshua T.
YR 2020
UL http://medrxiv.org/content/early/2020/04/06/2020.04.03.20051706.abstract
AB The SARS-CoV-2 pandemic demonstrates the need for accurate and convenient approaches to diagnose and therapeutically monitor respiratory viral infections. We demonstrated that self-sampling with foam swabs is well-tolerated and provides quantitative viral output concordant with flocked swabs. Using longitudinal home-based self-sampling, we demonstrate nasal cytokine levels correlate and cluster according to immune cell of origin. Periods of stable viral loads are followed by rapid elimination, which could be coupled with cytokine expansion and contraction using mathematical models. Nasal foam swab self-sampling at home provides a precise, mechanistic readout of respiratory virus shedding and local immune responses.Competing Interest StatementA.W.: Kyorin (personal fees), Ansun (research support), VB Tech (research support), all outside of the submitted work. A.G.: Abbott Molecular, personal fees, outside of the submitted work. M.B.: Kyorin (personal fees), Gilead (research support, personal fees), ReViral (personal fees_, Janssen (research support, personal fees), Ansun (research support, personal fees), Moderna (personal fees); Vir Bio (research support, personal fees); GSK (personal fees), Pulmocide (personal fees), VB Tech (research support), Bavarian Nordic (personal fees), DMA (personal fees), Allovir (personal fees), all outside of the submitted work.Funding StatementThis work was supported by the National Institutes of Health [grant numbers K24 HL093294-06 (M.B.), K23 AI114844-02 (A.W.)] and the Fred Hutchinson Cancer Center Vaccine and Infectious Diseases Faculty Initiative Fund (M.B. and J.S.).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.